Latest Shareholder Engagement News

Infinity Mining has raised A$1 million through a discounted placement to accelerate exploration in Victoria and advance its innovative mineral extraction partnership at the Cangai Project.

NuEnergy Gas Limited has announced a $4.62 million entitlement offer, primarily to fund early gas sales and development of its Indonesian coal bed methane assets. The offer is partially underwritten by a major shareholder and supports key milestones in the company’s transition to commercial production.

McLaren Minerals has launched a fully underwritten A$3.6 million entitlement offer to accelerate development of its McLaren titanium project, offering shareholders discounted shares and options.

4DS Memory Limited reveals a pivotal quarter marked by a strategic review, executive departures, and a contentious board nomination ahead of its AGM.

ANZ Group Holdings Limited has announced a 1.5% discount on shares acquired through its Dividend Reinvestment and Bonus Option Plans for the upcoming 2025 final dividend, signaling a subtle shift in shareholder incentives.

Locate Technologies has dispatched its Scheme Booklet to shareholders, outlining the proposed acquisition by Locate NZ and urging a vote in favour at the upcoming virtual meeting.

Aureka Limited reports significant drilling successes at its Victorian gold projects, confirming resource extensions and high-grade intercepts, while initiating a strategic review of its Tandarra joint venture.

MEC Resources has advanced its investment in Advent Energy and issued shares to directors, while its PEP 11 Joint Venture faces ongoing legal scrutiny ahead of a Federal Court hearing.

Noronex Limited has advanced its copper and uranium exploration with significant drilling results in Namibia and a strategic expansion into Botswana, backed by South32 funding and a recent capital raise.

James Hardie confirms key board changes and underscores its commitment to shareholder value amid strong integration progress with AZEK.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

Cann Group Limited has opened a $6.5 million Share Purchase Plan (SPP) alongside a placement, offering shareholders discounted shares with attaching options as it targets significant revenue growth in FY26.